Results for:(76 found)
Mar 28, 2013 10:50AM on Top StocksBy Benzinga

There's mixed interest in biotech, biopharmaceutical and emerging pharma companies.

Mar 11, 2013 9:27AM on Top StocksBy Benzinga

Look to these investments this week for strength as stocks continue to outperform.

Feb 13, 2013 4:46AM on Top StocksBy Gene Marcial

This biotech behemoth's appeal is its combined value-and-growth stock characteristics.

Feb 6, 2013 10:18AM on Top StocksBy Jim Cramer

Remember when I said you want to buy a pullback? Take a good, long look at these stellar names.

Feb 1, 2013 9:57AM on Top StocksBy Minyanville.com

The month also features a big gathering of biotech CEOs in New York and a cancer research meeting in Florida.

Jan 16, 2013 10:06AM on Top StocksBy Jim Cramer

Investors love the very companies they disdained just 6 months ago, and this turn of events is just getting started.

Jan 2, 2013 12:07PM on Top StocksBy TheStreet Staff

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.

Dec 12, 2012 2:38PM on Top StocksBy Minyanville.com

The $510 million acquisition of YM BioSciences is a low-risk deal for the big biotech, and has Incyte shareholders worried.

Tags: GILDINCY

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More